SCHEMBL5877349

SCHEMBL5877349

N#Cc1n[nH]c2c1C=CC(c1ccccc1)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 2/20 0.36
PIM1 P11309 1/20 0.33
FLT3 P36888 1/20 0.33
HCAR2 Q8TDS4 3/20 0.33
USP7 Q93009 1/20 0.33
GRK5 P34947 2/20 0.31
KDR P35968 2/20 0.31
MAP2K2 P36507 2/20 0.31
CDK8 P49336 2/20 0.31
GSK3A P49840 2/20 0.31
GSK3B P49841 2/20 0.31
LIMK1 P53667 2/20 0.31
MAP2K1 Q02750 2/20 0.31
DYRK1A Q13627 2/20 0.31
NTRK3 Q16288 2/20 0.31
NTRK2 Q16620 2/20 0.31
LRRK2 Q5S007 2/20 0.31
CAMK1D Q8IU85 2/20 0.31
CLK4 Q9HAZ1 2/20 0.31
DYRK1B Q9Y463 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876644 0.78 MAPK10 (0.46) PIM1FLT3HCAR2USP7KDR
SCHEMBL5876273 0.78 CSF1R (0.36) PIM1FLT3HCAR2GRK5KDR
SCHEMBL5877114 0.74 MKNK1 (0.40) PIM1FLT3HCAR2LMNAMAPK10
SCHEMBL5876901 0.72 LRRK2 (0.40) PIM1HCAR2LRRK2LMNAMAPK10
SCHEMBL5875946 0.71 ADORA2A (0.38) HCAR2KDRLMNAMAPK10FLT1
SCHEMBL5876817 0.71 KDM4E (0.39) HCAR2KDRLMNAMAPK10HTR7
SCHEMBL5877175 0.71 IDO1 (0.45) PIM1LRRK2LMNAMAPK10HTR7
SCHEMBL5875924 0.71 HCAR2 (0.38) PIM1FLT3HCAR2USP7LMNA
SCHEMBL5878102 0.71 IDO1 (0.42) PIM1FLT3HCAR2GRK5KDR
SCHEMBL5878112 0.71 HCAR2 (0.44) HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT ERBB2 214/4885PIM1 143/4885FLT3 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.